{"change_dates":[],"dossier":{"amendments":[],"changes":{"2013-01-31T01:21:00":[{"data":[{"body":"EC","commission":[{"Commissioner":"\u0160EMETA Algirdas","DG":{"title":"Taxation and Customs Union","url":"http://ec.europa.eu/taxation_customs/index_en.htm"}}],"date":"2013-01-21T00:00:00","docs":[{"celexid":"CELEX:52013PC0004:EN","title":"COM(2013)0004","type":"Legislative proposal published","url":"http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0004/COM_COM(2013)0004_EN.pdf"}],"type":"Legislative proposal"}],"path":["activities"],"type":"added"},{"data":[{"body":"EC","commissioner":"\u0160EMETA Algirdas","dg":{"title":"Taxation and Customs Union","url":"http://ec.europa.eu/taxation_customs/index_en.htm"}}],"path":["other"],"type":"added"},{"data":[{"body":"EP","committee":"ENVI","committee_full":"Environment, Public Health and Food Safety","responsible":false},{"body":"EP","committee":"INTA","committee_full":"International Trade","responsible":true},{"body":"EP","committee":"JURI","committee_full":"Legal Affairs","responsible":false},{"body":"EP","committee":"LIBE","committee_full":"Civil Liberties, Justice and Home Affairs","responsible":false}],"path":["committees"],"type":"added"},{"data":{"European Commission":{"title":"PreLex","url":"http://ec.europa.eu/prelex/liste_resultats.cfm?CL=en&ReqId=0&DocType=NLE&DocYear=2013&DocNum=0005"},"National parliaments":{"title":"IPEX","url":"http://www.ipex.eu/IPEXL-WEB/dossier/dossier.do?code=NLE&year=2013&number=0005&appLng=EN"}},"path":["links"],"type":"added"},{"data":{"geographical_area":["Russian Federation"],"legal_basis":["Treaty on the Functioning of the EU TFEU 207-p4","Treaty on the Functioning of the EU TFEU 218-p6a"],"reference":"2013/0005(NLE)","stage_reached":"Preparatory phase in Parliament","subject":["4.20.04 Pharmaceutical products and industry","6.20.02 Export/import control, trade defence","6.20.03 Bilateral economic and trade agreements and relations","7.30.30.04 Action to combat drugs and drug-trafficking"],"subtype":"Consent by Parliament","title":"EU/Russia agreement: drug precursors","type":"NLE - Non-legislative enactments"},"path":["procedure"],"type":"added"}],"2013-02-21T00:23:27":[{"data":["
PURPOSE: the conclusion of an agreement between the\nEuropean Union and the Russian Federation on drug\nprecursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENTS ROLE: Parliaments consent is\nrequired for the Council to conclude the agreement.
\nBACKGROUND: on 23 March 2009, the Council authorised\nthe Commission to open negotiations with the Russian Federation for\nan Agreement on drug precursors. Following the launch of\nnegotiations in September 2009, four negotiating rounds took\nplace.
\nIn September 2012, the text of the Agreement was\nfinally agreed between the Parties.
\nIt is now appropriate to conclude this Agreement on\nbehalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was\nundertaken. The Member States were, however, kept regularly\ninformed on the negotiations at the most appropriate level of the\nCouncil on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in\nconjunction with Article 218 (6) (a) of the Treaty on the\nFunctioning of the European Union (TFEU).
\nCONTENT: this Decision seeks to conclude an agreement\nbetween the European Union and Russia on drug\nprecursors.
\nPurpose of the Agreement: the Draft Agreement aims to strengthen the cooperation\nbetween the European Union and Russia to prevent diversion of\ndrug precursors from the legal trade to counter illicit manufacture\nof narcotic drugs and psychotropic substances.
\nScope: from a technical\npoint of view, it is stipulated that the Parties shall assist each\nother in the form and under the conditions provided for in the\nAgreement, in particular by:
\nThe measures shall apply to the precursors listed in\nAnnex I of the Agreement (referred to as \"scheduled\nprecursors\").
\nExceptions to the obligation to provide mutual\nassistance: provisions are made in\nthe Agreement for derogations from the principle of mutual\nassistance in cases where a Party is of the opinion that assistance\nunder this Agreement would be likely to prejudice the sovereignty\nthe security, the public policy or other essential\ninterests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange\nof personal data, it includes specific provisions on data\nprotection in order to provide sufficient protection for citizens\nin the use of their data. An annex clarifies certain definitions or\nprinciples relating to data protection.
\nScientific and technical cooperation:
\nProvisions are made to facilitate cooperation between\nthe Parties with a view to the identification of new diversion\nmethods, as well as appropriate counter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which\nconsists of the representatives of competent authorities of the\nParties. It shall be responsible for the management of the\nAgreement and its proper implementation.
\nIt should be noted that unless otherwise provided by\nthis Agreement, its provisions shall not affect the obligations of\nthe Parties under any other international agreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary\nimplications for the Union budget. Nevertheless, it is stipulated\nin the Agreement that each Party shall shall bear the costs it\nincurs arising from the measures to implement the\nAgreement.
\nPURPOSE: the conclusion of an agreement between the\nEuropean Union and the Russian Federation on drug\nprecursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENTS ROLE: Parliaments consent is\nrequired for the Council to conclude the agreement.
\nBACKGROUND: on 23 March 2009, the Council authorised\nthe Commission to open negotiations with the Russian Federation for\nan Agreement on drug precursors. Following the launch of\nnegotiations in September 2009, four negotiating rounds took\nplace.
\nIn September 2012, the text of the Agreement was\nfinally agreed between the Parties.
\nIt is now appropriate to conclude this Agreement on\nbehalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was\nundertaken. The Member States were, however, kept regularly\ninformed on the negotiations at the most appropriate level of the\nCouncil on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in\nconjunction with Article 218 (6) (a) of the Treaty on the\nFunctioning of the European Union (TFEU).
\nCONTENT: this Decision seeks to conclude an agreement\nbetween the European Union and Russia on drug\nprecursors.
\nPurpose of the Agreement: the Draft Agreement aims to strengthen the cooperation\nbetween the European Union and Russia to prevent diversion of\ndrug precursors from the legal trade to counter illicit manufacture\nof narcotic drugs and psychotropic substances.
\nScope: from a technical\npoint of view, it is stipulated that the Parties shall assist each\nother in the form and under the conditions provided for in the\nAgreement, in particular by:
\nThe measures shall apply to the precursors listed in\nAnnex I of the Agreement (referred to as \"scheduled\nprecursors\").
\nExceptions to the obligation to provide mutual\nassistance: provisions are made in\nthe Agreement for derogations from the principle of mutual\nassistance in cases where a Party is of the opinion that assistance\nunder this Agreement would be likely to prejudice the sovereignty\nthe security, the public policy or other essential\ninterests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange\nof personal data, it includes specific provisions on data\nprotection in order to provide sufficient protection for citizens\nin the use of their data. An annex clarifies certain definitions or\nprinciples relating to data protection.
\nScientific and technical cooperation:
\nProvisions are made to facilitate cooperation between\nthe Parties with a view to the identification of new diversion\nmethods, as well as appropriate counter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which\nconsists of the representatives of competent authorities of the\nParties. It shall be responsible for the management of the\nAgreement and its proper implementation.
\nIt should be noted that unless otherwise provided by\nthis Agreement, its provisions shall not affect the obligations of\nthe Parties under any other international agreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary\nimplications for the Union budget. Nevertheless, it is stipulated\nin the Agreement that each Party shall shall bear the costs it\nincurs arising from the measures to implement the\nAgreement.
\nPURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENT'S ROLE: Parliament's consent is required for the Council to conclude the agreement.
\nBACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place.
\nIn September 2012, the text of the Agreement was finally agreed between the Parties.
\nIt is now appropriate to conclude this Agreement on behalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).
\nCONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors.
\nPurpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.
\nScope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:
\nThe measures shall apply to the precursors listed in Annex I of the Agreement (referred to as \"scheduled precursors\").
\nExceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.
\nScientific and technical cooperation:
\nProvisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.
\nIt should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement. \n\t\t \t\t\t\t\t\t
PURPOSE: the conclusion of an agreement between the\nEuropean Union and Russia on drug precursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENTS ROLE: Parliaments consent is\nrequired for the Council to conclude the agreement.
\nBACKGROUND: the European Union and the Russian\nFederation should strengthen their cooperation to prevent diversion\nof drug precursors from the legal trade, in order to counter the\nillicit manufacture of narcotic drugs and psychotropic\nsubstances.
\nIn accordance with a Council Decision, the Agreement\nbetween the European Union and the Russian Federation on drug\nprecursors was signed on 4 June 2013, subject to its conclusion at\na later date.
\nThe Agreement should ensure full respect of\nfundamental rights, in particular a high level of protection for\nthe processing and transfer of personal data between the Parties to\nthe Agreement.
\nIt is now appropriate to conclude this Agreement on\nbehalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was\nundertaken. The Member States were, however, kept regularly\ninformed on the negotiations at the most appropriate level of the\nCouncil on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in\nconjunction with Article 218 (6) (a) of the Treaty on the\nFunctioning of the European Union (TFEU).
\nCONTENT: by this proposal, the Council is invited to\nadopt a decision on the conclusion of an agreement between the\nEuropean Union and Russia on drug precursors.
\nThe text of the Agreement is\nattached to the proposed Decision. Its main characteristics may be\nsummarised as follows:
\nPurpose of the Agreement: the draft Agreement aims to strengthen the cooperation\nbetween the European Union and Russia to prevent diversion of\ndrug precursors from the legal trade to counter illicit manufacture\nof narcotic drugs and psychotropic substances.
\nScope: from a technical\npoint of view, it is stipulated that the Parties shall assist each\nother in the form and under the conditions provided for in the\nAgreement, in particular by:
\nThe measures shall apply to the precursors listed in\nAnnex I of the Agreement (referred to as \"scheduled\nprecursors\").
\nImplementation measures: the Parties shall inform each other in writing about\ntheir respective competent authorities. These authorities shall\ncommunicate directly with one another for the purposes of this\nAgreement. The competent authorities of the Parties shall inform\neach other on their own initiative whenever they have\nreasonable grounds to believe that scheduled precursors in\nlegitimate trade between the Parties may be diverted to the illicit\nmanufacture of narcotic drugs or psychotropic\nsubstances.
\nThe Parties shall within the scope of this agreement\nprovide each other mutual assistance through exchange of\ninformation referred to in the draft Agreement to prevent the\ndiversion of scheduled precursors to the illicit manufacture of\nnarcotic drugs or psychotropic substances. They shall, in\naccordance with the legislation of the Parties, take appropriate\nsteps to prevent diversion.
\nExceptions to the obligation to provide mutual\nassistance: provisions are made in\nthe Agreement for derogations from the principle of mutual\nassistance in cases where a Party is of the opinion that assistance\nunder this Agreement would be likely to prejudice the sovereignty\nthe security, the public policy or other essential\ninterests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange\nof personal data, it includes specific provisions on data\nprotection in order to provide sufficient protection for citizens\nin the use of their data. An annex clarifies certain definitions or\nprinciples relating to data protection.
\nScientific and technical cooperation: provisions are made to\nfacilitate cooperation between the Parties with a view to the\nidentification of new diversion methods, as well as appropriate\ncounter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which\nconsists of the representatives of competent authorities of the\nParties. It shall be responsible for the management of the\nAgreement and its proper implementation.
\nDuration of the Agreement: this Agreement shall be concluded for five years at\nthe end of which it is automatically/tacitly renewed for further\nsuccessive five year periods until one of the Parties notifies the\nother Party in writing of its intention to terminate this present\nagreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary\nimplications for the Union budget. Nevertheless, it is stipulated\nin the Agreement that each Party shall bear the costs it incurs\narising from the measures to implement the Agreement.
\nPURPOSE: the conclusion of an agreement between the\nEuropean Union and Russia on drug precursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENTS ROLE: Parliaments consent is\nrequired for the Council to conclude the agreement.
\nBACKGROUND: the European Union and the Russian\nFederation should strengthen their cooperation to prevent diversion\nof drug precursors from the legal trade, in order to counter the\nillicit manufacture of narcotic drugs and psychotropic\nsubstances.
\nIn accordance with a Council Decision, the Agreement\nbetween the European Union and the Russian Federation on drug\nprecursors was signed on 4 June 2013, subject to its conclusion at\na later date.
\nThe Agreement should ensure full respect of\nfundamental rights, in particular a high level of protection for\nthe processing and transfer of personal data between the Parties to\nthe Agreement.
\nIt is now appropriate to conclude this Agreement on\nbehalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was\nundertaken. The Member States were, however, kept regularly\ninformed on the negotiations at the most appropriate level of the\nCouncil on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in\nconjunction with Article 218 (6) (a) of the Treaty on the\nFunctioning of the European Union (TFEU).
\nCONTENT: by this proposal, the Council is invited to\nadopt a decision on the conclusion of an agreement between the\nEuropean Union and Russia on drug precursors.
\nThe text of the Agreement is\nattached to the proposed Decision. Its main characteristics may be\nsummarised as follows:
\nPurpose of the Agreement: the draft Agreement aims to strengthen the cooperation\nbetween the European Union and Russia to prevent diversion of\ndrug precursors from the legal trade to counter illicit manufacture\nof narcotic drugs and psychotropic substances.
\nScope: from a technical\npoint of view, it is stipulated that the Parties shall assist each\nother in the form and under the conditions provided for in the\nAgreement, in particular by:
\nThe measures shall apply to the precursors listed in\nAnnex I of the Agreement (referred to as \"scheduled\nprecursors\").
\nImplementation measures: the Parties shall inform each other in writing about\ntheir respective competent authorities. These authorities shall\ncommunicate directly with one another for the purposes of this\nAgreement. The competent authorities of the Parties shall inform\neach other on their own initiative whenever they have\nreasonable grounds to believe that scheduled precursors in\nlegitimate trade between the Parties may be diverted to the illicit\nmanufacture of narcotic drugs or psychotropic\nsubstances.
\nThe Parties shall within the scope of this agreement\nprovide each other mutual assistance through exchange of\ninformation referred to in the draft Agreement to prevent the\ndiversion of scheduled precursors to the illicit manufacture of\nnarcotic drugs or psychotropic substances. They shall, in\naccordance with the legislation of the Parties, take appropriate\nsteps to prevent diversion.
\nExceptions to the obligation to provide mutual\nassistance: provisions are made in\nthe Agreement for derogations from the principle of mutual\nassistance in cases where a Party is of the opinion that assistance\nunder this Agreement would be likely to prejudice the sovereignty\nthe security, the public policy or other essential\ninterests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange\nof personal data, it includes specific provisions on data\nprotection in order to provide sufficient protection for citizens\nin the use of their data. An annex clarifies certain definitions or\nprinciples relating to data protection.
\nScientific and technical cooperation: provisions are made to\nfacilitate cooperation between the Parties with a view to the\nidentification of new diversion methods, as well as appropriate\ncounter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which\nconsists of the representatives of competent authorities of the\nParties. It shall be responsible for the management of the\nAgreement and its proper implementation.
\nDuration of the Agreement: this Agreement shall be concluded for five years at\nthe end of which it is automatically/tacitly renewed for further\nsuccessive five year periods until one of the Parties notifies the\nother Party in writing of its intention to terminate this present\nagreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary\nimplications for the Union budget. Nevertheless, it is stipulated\nin the Agreement that each Party shall bear the costs it incurs\narising from the measures to implement the Agreement.
\nThe Committee on International Trade adopted the\nreport by Franck PROUST (EPP, FR) on the draft Council Decision on\nthe conclusion, on behalf of the European Union, of the Agreement\nbetween the European Union and the Russian Federation on drug\nprecursors.
\nIt recommended that the European Parliament give its\nconsent to the conclusion. It also indicated that it would be\nnecessary to monitor its implementation and that it hoped for the\nconclusion to be followed up by other similar agreements with other\nthird countries in the years to come.
\nThe European Parliament adopted a legislative\nresolution on the on the draft Council Decision on the conclusion,\non behalf of the European Union, of the Agreement between the\nEuropean Union and the Russian Federation on drug\nprecursors.
\nParliament gave its consent to the conclusion of the\nAgreement.
\nPURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENT'S ROLE: Parliament's consent is required for the Council to conclude the agreement.
\nBACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place.
\nIn September 2012, the text of the Agreement was finally agreed between the Parties.
\nIt is now appropriate to conclude this Agreement on behalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).
\nCONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors.
\nPurpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.
\nScope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:
\nThe measures shall apply to the precursors listed in Annex I of the Agreement (referred to as \"scheduled precursors\").
\nExceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.
\nScientific and technical cooperation:
\nProvisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.
\nIt should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement. \n\t\t \t\t\t\t\t\t
PURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENT'S ROLE: Parliament's consent is required for the Council to conclude the agreement.
\nBACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place.
\nIn September 2012, the text of the Agreement was finally agreed between the Parties.
\nIt is now appropriate to conclude this Agreement on behalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).
\nCONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors.
\nPurpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.
\nScope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:
\nThe measures shall apply to the precursors listed in Annex I of the Agreement (referred to as \"scheduled precursors\").
\nExceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.
\nScientific and technical cooperation:
\nProvisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.
\nIt should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement. \n\t\t \t\t\t\t\t\t
PURPOSE: the conclusion of an agreement between the\nEuropean Union and Russia on drug precursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENTS ROLE: Parliaments consent is\nrequired for the Council to conclude the agreement.
\nBACKGROUND: the European Union and the Russian\nFederation should strengthen their cooperation to prevent diversion\nof drug precursors from the legal trade, in order to counter the\nillicit manufacture of narcotic drugs and psychotropic\nsubstances.
\nIn accordance with a Council Decision, the Agreement\nbetween the European Union and the Russian Federation on drug\nprecursors was signed on 4 June 2013, subject to its conclusion at\na later date.
\nThe Agreement should ensure full respect of\nfundamental rights, in particular a high level of protection for\nthe processing and transfer of personal data between the Parties to\nthe Agreement.
\nIt is now appropriate to conclude this Agreement on\nbehalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was\nundertaken. The Member States were, however, kept regularly\ninformed on the negotiations at the most appropriate level of the\nCouncil on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in\nconjunction with Article 218 (6) (a) of the Treaty on the\nFunctioning of the European Union (TFEU).
\nCONTENT: by this proposal, the Council is invited to\nadopt a decision on the conclusion of an agreement between the\nEuropean Union and Russia on drug precursors.
\nThe text of the Agreement is\nattached to the proposed Decision. Its main characteristics may be\nsummarised as follows:
\nPurpose of the Agreement: the draft Agreement aims to strengthen the cooperation\nbetween the European Union and Russia to prevent diversion of\ndrug precursors from the legal trade to counter illicit manufacture\nof narcotic drugs and psychotropic substances.
\nScope: from a technical\npoint of view, it is stipulated that the Parties shall assist each\nother in the form and under the conditions provided for in the\nAgreement, in particular by:
\nThe measures shall apply to the precursors listed in\nAnnex I of the Agreement (referred to as \"scheduled\nprecursors\").
\nImplementation measures: the Parties shall inform each other in writing about\ntheir respective competent authorities. These authorities shall\ncommunicate directly with one another for the purposes of this\nAgreement. The competent authorities of the Parties shall inform\neach other on their own initiative whenever they have\nreasonable grounds to believe that scheduled precursors in\nlegitimate trade between the Parties may be diverted to the illicit\nmanufacture of narcotic drugs or psychotropic\nsubstances.
\nThe Parties shall within the scope of this agreement\nprovide each other mutual assistance through exchange of\ninformation referred to in the draft Agreement to prevent the\ndiversion of scheduled precursors to the illicit manufacture of\nnarcotic drugs or psychotropic substances. They shall, in\naccordance with the legislation of the Parties, take appropriate\nsteps to prevent diversion.
\nExceptions to the obligation to provide mutual\nassistance: provisions are made in\nthe Agreement for derogations from the principle of mutual\nassistance in cases where a Party is of the opinion that assistance\nunder this Agreement would be likely to prejudice the sovereignty\nthe security, the public policy or other essential\ninterests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange\nof personal data, it includes specific provisions on data\nprotection in order to provide sufficient protection for citizens\nin the use of their data. An annex clarifies certain definitions or\nprinciples relating to data protection.
\nScientific and technical cooperation: provisions are made to\nfacilitate cooperation between the Parties with a view to the\nidentification of new diversion methods, as well as appropriate\ncounter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which\nconsists of the representatives of competent authorities of the\nParties. It shall be responsible for the management of the\nAgreement and its proper implementation.
\nDuration of the Agreement: this Agreement shall be concluded for five years at\nthe end of which it is automatically/tacitly renewed for further\nsuccessive five year periods until one of the Parties notifies the\nother Party in writing of its intention to terminate this present\nagreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary\nimplications for the Union budget. Nevertheless, it is stipulated\nin the Agreement that each Party shall bear the costs it incurs\narising from the measures to implement the Agreement.
\nPURPOSE: the conclusion of\nan agreement between the European Union and the Russian Federation\non drug precursors.
\nNON-LEGISLATIVE ACT: Council Decision 2014/318/EU on the\nconclusion, on behalf of the European Union, of the Agreement\nbetween the European Union and the Russian Federation on drug\nprecursors.
\nBACKGROUND: the European\nUnion and the Russian Federation should strengthen their\ncooperation to prevent diversion of drug precursors from the legal\ntrade, in order to counter the illicit manufacture of narcotic\ndrugs and psychotropic substances.
\nIn accordance with Council Decision 2013/263/EU, the\nAgreement between the European Union and the Russian Federation on\ndrug precursors was signed on 4 June 2013, subject to its\nconclusion at a later date.
\nThe Agreement should ensure full respect of\nfundamental rights, in particular a high level of protection for\nthe processing and transfer of personal data between the Parties to\nthe Agreement.
\nIt is now appropriate to conclude this agreement on\nbehalf of the European Union.
\nCONTENT: by means of this decision, the Council\napproves on behalf of the European Union, with the consent of the\nEuropean Parliament, an agreement between\nthe European Union and the Russian Federation on drug\nprecursors.
\nObjective of the agreement: the agreement aims to strengthen the cooperation\nbetween the European Union and Russia to prevent diversion\nof drug precursors from the legal trade to counter illicit\nmanufacture of narcotic drugs and psychotropic\nsubstances.
\nScope: from a technical\npoint of view, it is stipulated that the Parties shall assist each\nother in the form and under the conditions provided for in the\nAgreement, in particular by:
\n\n· \nmonitoring the trade between the Parties in the\nprecursors with the aim of preventing their use for illicit\npurposes,
\n\n· \nproviding mutual assistance for the purpose of\nprevention of diversion of such precursors.
\nThe measures shall apply to the precursors listed in\nAnnex I of the Agreement (referred to as \"scheduled\nprecursors\").
\nImplementing measures: it is envisaged that the Parties shall inform each\nother in writing about their respective competent authorities.\nThese authorities shall communicate directly with one another for\nthe purposes of this Agreement. The competent authorities of the\nParties shall inform each other on their own initiative whenever\nthey have reasonable grounds to believe that scheduled precursors\nin legitimate trade between the Parties may be diverted to the\nillicit manufacture of narcotic drugs or psychotropic\nsubstances.
\nExceptions to the obligation to provide mutual\nassistance: provisions are made in\nthe Agreement for derogations from the principle of mutual\nassistance in cases where a Party is of the opinion that\nassistance under this Agreement would be likely to prejudice the\nsovereignty the security, the public policy or other essential\ninterests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange\nof personal data, it includes specific provisions on data\nprotection in order to provide sufficient protection for citizens\nin the use of their data. An annex clarifies certain definitions or\nprinciples relating to data protection.
\nScientific and technical cooperation: provisions are made to facilitate cooperation between\nthe Parties with a view to the identification of new diversion\nmethods, as well as appropriate counter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which\nconsists of the representatives of competent authorities of the\nParties. It shall be responsible for the management of the\nAgreement and its proper implementation.
\nDuration of the agreement: the agreement is concluded\nfor a period of 5 years at the end of which it will be\nautomatically/tacitly renewed for successive new periods of 5\nyears, until one of the Parties notifies the other in writing of\nits intention to terminate the agreement. It may be amended by\ncommon agreement.
\nENTRY INTO FORCE: the decision enters into force on\n17.02.2014. The agreement enters into force on 1 April\n2014.
\nPURPOSE: the conclusion of an agreement between the European Union and the Russian Federation on drug precursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENT'S ROLE: Parliament's consent is required for the Council to conclude the agreement.
\nBACKGROUND: on 23 March 2009, the Council authorised the Commission to open negotiations with the Russian Federation for an Agreement on drug precursors. Following the launch of negotiations in September 2009, four negotiating rounds took place.
\nIn September 2012, the text of the Agreement was finally agreed between the Parties.
\nIt is now appropriate to conclude this Agreement on behalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was undertaken. The Member States were, however, kept regularly informed on the negotiations at the most appropriate level of the Council on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in conjunction with Article 218 (6) (a) of the Treaty on the Functioning of the European Union (TFEU).
\nCONTENT: this Decision seeks to conclude an agreement between the European Union and Russia on drug precursors.
\nPurpose of the Agreement: the Draft Agreement aims to strengthen the cooperation between the European Union and Russia to prevent diversion of drug precursors from the legal trade to counter illicit manufacture of narcotic drugs and psychotropic substances.
\nScope: from a technical point of view, it is stipulated that the Parties shall assist each other in the form and under the conditions provided for in the Agreement, in particular by:
\nThe measures shall apply to the precursors listed in Annex I of the Agreement (referred to as \"scheduled precursors\").
\nExceptions to the obligation to provide mutual assistance: provisions are made in the Agreement for derogations from the principle of mutual assistance in cases where a Party is of the opinion that assistance under this Agreement would be likely to prejudice the sovereignty the security, the public policy or other essential interests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange of personal data, it includes specific provisions on data protection in order to provide sufficient protection for citizens in the use of their data. An annex clarifies certain definitions or principles relating to data protection.
\nScientific and technical cooperation:
\nProvisions are made to facilitate cooperation between the Parties with a view to the identification of new diversion methods, as well as appropriate counter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which consists of the representatives of competent authorities of the Parties. It shall be responsible for the management of the Agreement and its proper implementation.
\nIt should be noted that unless otherwise provided by this Agreement, its provisions shall not affect the obligations of the Parties under any other international agreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary implications for the Union budget. Nevertheless, it is stipulated in the Agreement that each Party shall shall bear the costs it incurs arising from the measures to implement the Agreement. \n\t\t \t\t\t\t\t\t
PURPOSE: the conclusion of an agreement between the\nEuropean Union and Russia on drug precursors.
\nPROPOSED ACT: Council Decision.
\nPARLIAMENTS ROLE: Parliaments consent is\nrequired for the Council to conclude the agreement.
\nBACKGROUND: the European Union and the Russian\nFederation should strengthen their cooperation to prevent diversion\nof drug precursors from the legal trade, in order to counter the\nillicit manufacture of narcotic drugs and psychotropic\nsubstances.
\nIn accordance with a Council Decision, the Agreement\nbetween the European Union and the Russian Federation on drug\nprecursors was signed on 4 June 2013, subject to its conclusion at\na later date.
\nThe Agreement should ensure full respect of\nfundamental rights, in particular a high level of protection for\nthe processing and transfer of personal data between the Parties to\nthe Agreement.
\nIt is now appropriate to conclude this Agreement on\nbehalf of the European Union.
\nIMPACT ASSESSMENT: no impact assessment was\nundertaken. The Member States were, however, kept regularly\ninformed on the negotiations at the most appropriate level of the\nCouncil on the Draft Agreement.
\nLEGAL BASIS: Article 207 (4) first indent in\nconjunction with Article 218 (6) (a) of the Treaty on the\nFunctioning of the European Union (TFEU).
\nCONTENT: by this proposal, the Council is invited to\nadopt a decision on the conclusion of an agreement between the\nEuropean Union and Russia on drug precursors.
\nThe text of the Agreement is\nattached to the proposed Decision. Its main characteristics may be\nsummarised as follows:
\nPurpose of the Agreement: the draft Agreement aims to strengthen the cooperation\nbetween the European Union and Russia to prevent diversion of\ndrug precursors from the legal trade to counter illicit manufacture\nof narcotic drugs and psychotropic substances.
\nScope: from a technical\npoint of view, it is stipulated that the Parties shall assist each\nother in the form and under the conditions provided for in the\nAgreement, in particular by:
\nThe measures shall apply to the precursors listed in\nAnnex I of the Agreement (referred to as \"scheduled\nprecursors\").
\nImplementation measures: the Parties shall inform each other in writing about\ntheir respective competent authorities. These authorities shall\ncommunicate directly with one another for the purposes of this\nAgreement. The competent authorities of the Parties shall inform\neach other on their own initiative whenever they have\nreasonable grounds to believe that scheduled precursors in\nlegitimate trade between the Parties may be diverted to the illicit\nmanufacture of narcotic drugs or psychotropic\nsubstances.
\nThe Parties shall within the scope of this agreement\nprovide each other mutual assistance through exchange of\ninformation referred to in the draft Agreement to prevent the\ndiversion of scheduled precursors to the illicit manufacture of\nnarcotic drugs or psychotropic substances. They shall, in\naccordance with the legislation of the Parties, take appropriate\nsteps to prevent diversion.
\nExceptions to the obligation to provide mutual\nassistance: provisions are made in\nthe Agreement for derogations from the principle of mutual\nassistance in cases where a Party is of the opinion that assistance\nunder this Agreement would be likely to prejudice the sovereignty\nthe security, the public policy or other essential\ninterests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange\nof personal data, it includes specific provisions on data\nprotection in order to provide sufficient protection for citizens\nin the use of their data. An annex clarifies certain definitions or\nprinciples relating to data protection.
\nScientific and technical cooperation: provisions are made to\nfacilitate cooperation between the Parties with a view to the\nidentification of new diversion methods, as well as appropriate\ncounter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which\nconsists of the representatives of competent authorities of the\nParties. It shall be responsible for the management of the\nAgreement and its proper implementation.
\nDuration of the Agreement: this Agreement shall be concluded for five years at\nthe end of which it is automatically/tacitly renewed for further\nsuccessive five year periods until one of the Parties notifies the\nother Party in writing of its intention to terminate this present\nagreement.
\nBUDGETARY IMPLICATION: the proposal has no budgetary\nimplications for the Union budget. Nevertheless, it is stipulated\nin the Agreement that each Party shall bear the costs it incurs\narising from the measures to implement the Agreement.
\nThe Committee on International Trade adopted the\nreport by Franck PROUST (EPP, FR) on the draft Council Decision on\nthe conclusion, on behalf of the European Union, of the Agreement\nbetween the European Union and the Russian Federation on drug\nprecursors.
\nIt recommended that the European Parliament give its\nconsent to the conclusion. It also indicated that it would be\nnecessary to monitor its implementation and that it hoped for the\nconclusion to be followed up by other similar agreements with other\nthird countries in the years to come.
\nThe European Parliament adopted a legislative\nresolution on the on the draft Council Decision on the conclusion,\non behalf of the European Union, of the Agreement between the\nEuropean Union and the Russian Federation on drug\nprecursors.
\nParliament gave its consent to the conclusion of the\nAgreement.
\nPURPOSE: the conclusion of\nan agreement between the European Union and the Russian Federation\non drug precursors.
\nNON-LEGISLATIVE ACT: Council Decision 2014/318/EU on the\nconclusion, on behalf of the European Union, of the Agreement\nbetween the European Union and the Russian Federation on drug\nprecursors.
\nBACKGROUND: the European\nUnion and the Russian Federation should strengthen their\ncooperation to prevent diversion of drug precursors from the legal\ntrade, in order to counter the illicit manufacture of narcotic\ndrugs and psychotropic substances.
\nIn accordance with Council Decision 2013/263/EU, the\nAgreement between the European Union and the Russian Federation on\ndrug precursors was signed on 4 June 2013, subject to its\nconclusion at a later date.
\nThe Agreement should ensure full respect of\nfundamental rights, in particular a high level of protection for\nthe processing and transfer of personal data between the Parties to\nthe Agreement.
\nIt is now appropriate to conclude this agreement on\nbehalf of the European Union.
\nCONTENT: by means of this decision, the Council\napproves on behalf of the European Union, with the consent of the\nEuropean Parliament, an agreement between\nthe European Union and the Russian Federation on drug\nprecursors.
\nObjective of the agreement: the agreement aims to strengthen the cooperation\nbetween the European Union and Russia to prevent diversion\nof drug precursors from the legal trade to counter illicit\nmanufacture of narcotic drugs and psychotropic\nsubstances.
\nScope: from a technical\npoint of view, it is stipulated that the Parties shall assist each\nother in the form and under the conditions provided for in the\nAgreement, in particular by:
\n\n· \nmonitoring the trade between the Parties in the\nprecursors with the aim of preventing their use for illicit\npurposes,
\n\n· \nproviding mutual assistance for the purpose of\nprevention of diversion of such precursors.
\nThe measures shall apply to the precursors listed in\nAnnex I of the Agreement (referred to as \"scheduled\nprecursors\").
\nImplementing measures: it is envisaged that the Parties shall inform each\nother in writing about their respective competent authorities.\nThese authorities shall communicate directly with one another for\nthe purposes of this Agreement. The competent authorities of the\nParties shall inform each other on their own initiative whenever\nthey have reasonable grounds to believe that scheduled precursors\nin legitimate trade between the Parties may be diverted to the\nillicit manufacture of narcotic drugs or psychotropic\nsubstances.
\nExceptions to the obligation to provide mutual\nassistance: provisions are made in\nthe Agreement for derogations from the principle of mutual\nassistance in cases where a Party is of the opinion that\nassistance under this Agreement would be likely to prejudice the\nsovereignty the security, the public policy or other essential\ninterests.
\nExchange of personal data: as this Agreement may occasionally imply an exchange\nof personal data, it includes specific provisions on data\nprotection in order to provide sufficient protection for citizens\nin the use of their data. An annex clarifies certain definitions or\nprinciples relating to data protection.
\nScientific and technical cooperation: provisions are made to facilitate cooperation between\nthe Parties with a view to the identification of new diversion\nmethods, as well as appropriate counter-measures.
\nInstitutional framework: a Joint Follow-Up Expert Group is established which\nconsists of the representatives of competent authorities of the\nParties. It shall be responsible for the management of the\nAgreement and its proper implementation.
\nDuration of the agreement: the agreement is concluded\nfor a period of 5 years at the end of which it will be\nautomatically/tacitly renewed for successive new periods of 5\nyears, until one of the Parties notifies the other in writing of\nits intention to terminate the agreement. It may be amended by\ncommon agreement.
\nENTRY INTO FORCE: the decision enters into force on\n17.02.2014. The agreement enters into force on 1 April\n2014.
\n